ZA201806444B - Prodrug of amino acid derivative - Google Patents
Prodrug of amino acid derivativeInfo
- Publication number
- ZA201806444B ZA201806444B ZA2018/06444A ZA201806444A ZA201806444B ZA 201806444 B ZA201806444 B ZA 201806444B ZA 2018/06444 A ZA2018/06444 A ZA 2018/06444A ZA 201806444 A ZA201806444 A ZA 201806444A ZA 201806444 B ZA201806444 B ZA 201806444B
- Authority
- ZA
- South Africa
- Prior art keywords
- prodrug
- amino acid
- acid derivative
- derivative
- amino
- Prior art date
Links
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/48—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing ten carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016083147 | 2016-04-18 | ||
| PCT/JP2017/016125 WO2017183734A1 (en) | 2016-04-18 | 2017-04-18 | Prodrug of amino acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201806444B true ZA201806444B (en) | 2020-01-29 |
Family
ID=58737797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/06444A ZA201806444B (en) | 2016-04-18 | 2018-09-27 | Prodrug of amino acid derivative |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10464884B2 (en) |
| EP (1) | EP3445743B1 (en) |
| JP (2) | JP7045321B2 (en) |
| KR (1) | KR102444718B1 (en) |
| CN (1) | CN109071418B (en) |
| AU (1) | AU2017254266B2 (en) |
| BR (1) | BR112018069959B1 (en) |
| CA (1) | CA3019097C (en) |
| CY (1) | CY1124574T1 (en) |
| DK (1) | DK3445743T3 (en) |
| ES (1) | ES2886442T3 (en) |
| HR (1) | HRP20211277T1 (en) |
| HU (1) | HUE056046T2 (en) |
| IL (1) | IL262233B (en) |
| LT (1) | LT3445743T (en) |
| MX (1) | MX2018012442A (en) |
| MY (1) | MY195208A (en) |
| NZ (1) | NZ747061A (en) |
| PH (1) | PH12018502211A1 (en) |
| PL (1) | PL3445743T3 (en) |
| PT (1) | PT3445743T (en) |
| RS (1) | RS62515B1 (en) |
| RU (1) | RU2739318C2 (en) |
| SG (2) | SG10202006019YA (en) |
| SI (1) | SI3445743T1 (en) |
| TW (1) | TWI738767B (en) |
| WO (1) | WO2017183734A1 (en) |
| ZA (1) | ZA201806444B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444718B1 (en) * | 2016-04-18 | 2022-09-16 | 다이쇼 세이야꾸 가부시끼가이샤 | Prodrugs of amino acid derivatives |
| JP7314494B2 (en) * | 2017-10-17 | 2023-07-26 | 大正製薬株式会社 | Pharmaceuticals containing prodrugs of amino acid derivatives |
| EP4321164A3 (en) * | 2018-04-24 | 2024-04-17 | ViiV Healthcare UK (No.5) Limited | Compounds with hiv maturation inhibitory activity |
| CN109180712B (en) * | 2018-08-08 | 2020-12-25 | 南京医科大学 | 2-arrowhead alcohol arylboronic acid ester derivatives and application thereof |
| CN108948077B (en) * | 2018-08-09 | 2020-10-13 | 东华理工大学 | Alpha-phosphorylated alpha-amino acid ester compound and synthesis method thereof |
| JPWO2022114135A1 (en) * | 2020-11-26 | 2022-06-02 | ||
| CN112409443B (en) * | 2021-01-25 | 2021-04-27 | 潍坊科技学院 | Proteborl derivative, preparation method thereof and application thereof in preparation of medicines for treating cardiovascular and cerebrovascular diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045898A1 (en) * | 2001-11-23 | 2003-06-05 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| NZ533699A (en) * | 2001-12-27 | 2006-05-26 | Taisho Pharmaceutical Co Ltd | 6-fluorobicyclo[3.1.0]hexane derivatives |
| WO2005000791A1 (en) | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative |
| EP2502903A4 (en) | 2009-11-19 | 2013-04-17 | Taisho Pharmaceutical Co Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| WO2012068041A1 (en) * | 2010-11-18 | 2012-05-24 | Eli Lilly And Company | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
| AR083845A1 (en) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | 3-PHENYLSULPHANYLME-BICYCLE COMPOUNDS [3.1.0] HEXANE 4-REPLACED AS ANTAGONISTS OF mGluR2 / 3 |
| WO2013062680A1 (en) | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| EP2857385B1 (en) | 2012-06-01 | 2017-08-02 | Taisho Pharmaceutical Co., Ltd. | Prodrug of fluorine-containing amino acid |
| US20150119345A1 (en) | 2013-10-29 | 2015-04-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of gastrointestinal infections |
| KR102444718B1 (en) * | 2016-04-18 | 2022-09-16 | 다이쇼 세이야꾸 가부시끼가이샤 | Prodrugs of amino acid derivatives |
-
2017
- 2017-04-18 KR KR1020187029353A patent/KR102444718B1/en active IP Right Grant
- 2017-04-18 CN CN201780024360.7A patent/CN109071418B/en active Active
- 2017-04-18 BR BR112018069959-4A patent/BR112018069959B1/en active IP Right Grant
- 2017-04-18 SG SG10202006019YA patent/SG10202006019YA/en unknown
- 2017-04-18 AU AU2017254266A patent/AU2017254266B2/en active Active
- 2017-04-18 DK DK17724459.7T patent/DK3445743T3/en active
- 2017-04-18 ES ES17724459T patent/ES2886442T3/en active Active
- 2017-04-18 JP JP2018552900A patent/JP7045321B2/en active Active
- 2017-04-18 MY MYPI2018703815A patent/MY195208A/en unknown
- 2017-04-18 US US15/765,903 patent/US10464884B2/en active Active
- 2017-04-18 PL PL17724459T patent/PL3445743T3/en unknown
- 2017-04-18 PT PT177244597T patent/PT3445743T/en unknown
- 2017-04-18 MX MX2018012442A patent/MX2018012442A/en unknown
- 2017-04-18 RU RU2018140250A patent/RU2739318C2/en active
- 2017-04-18 RS RS20211289A patent/RS62515B1/en unknown
- 2017-04-18 NZ NZ747061A patent/NZ747061A/en unknown
- 2017-04-18 HU HUE17724459A patent/HUE056046T2/en unknown
- 2017-04-18 WO PCT/JP2017/016125 patent/WO2017183734A1/en active Application Filing
- 2017-04-18 SG SG11201808387PA patent/SG11201808387PA/en unknown
- 2017-04-18 EP EP17724459.7A patent/EP3445743B1/en active Active
- 2017-04-18 LT LTEPPCT/JP2017/016125T patent/LT3445743T/en unknown
- 2017-04-18 TW TW106112946A patent/TWI738767B/en active
- 2017-04-18 CA CA3019097A patent/CA3019097C/en active Active
- 2017-04-18 SI SI201730877T patent/SI3445743T1/en unknown
-
2018
- 2018-09-27 ZA ZA2018/06444A patent/ZA201806444B/en unknown
- 2018-10-09 IL IL262233A patent/IL262233B/en unknown
- 2018-10-16 PH PH12018502211A patent/PH12018502211A1/en unknown
-
2019
- 2019-07-15 US US16/511,349 patent/US10689327B2/en active Active
-
2020
- 2020-12-22 JP JP2020212361A patent/JP2021063095A/en not_active Withdrawn
-
2021
- 2021-08-09 HR HRP20211277TT patent/HRP20211277T1/en unknown
- 2021-10-08 CY CY20211100876T patent/CY1124574T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248570A1 (en) | D2o stabilized pharmaceutical formulations | |
| SG11201706729SA (en) | Derivatives of sobetirome | |
| IL262233B (en) | Prodrug of amino acid derivative | |
| IL263050B (en) | Derivatives of sobetirome | |
| EP3517528A4 (en) | Acid addition salt of benzimidazole derivative | |
| IL265856A (en) | Formulations for administration of eflornithine | |
| HK1252648A1 (en) | Amino acid supplementation | |
| GB201522764D0 (en) | Formulations of phosphate derivatives | |
| IL265138B (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| EP3414256A4 (en) | Amine salt of obeticholic acid | |
| HUE061332T2 (en) | Method for the preparation of aminobenzoic acid or an aminobenzoic acid derivative | |
| IL259394B (en) | Amine prodrugs of pharmaceutical compounds | |
| DK3200779T3 (en) | Novel anthranilic acid derivatives | |
| IL260369A (en) | Inhibition of protein degradation for improved production | |
| HK1252767A1 (en) | Pyrazol-pyridine derivatives as eaat3 inhibitors | |
| HUE059048T2 (en) | Process for the preparation of aminobenzoic acid or an aminobenzoic acid derivative | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| PL3484875T3 (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| EP3337479A4 (en) | Novel polymorphs of dolutegravir and salts thereof | |
| EP3176150A4 (en) | Medium-chain acyl basic amino acid derivative | |
| IL266121A (en) | Substituted quinoxaline derivatives as inhibitors of pfkfb | |
| IL263363A (en) | Polymorph of nintedanib | |
| HUP1600415A2 (en) | Pimavanserin salts for the manufacture of pharmaceutical formulations | |
| GB201616201D0 (en) | Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors |